Skip to main content
Home
Articles
Latest Issue
Issue Archive
Online First
Special Issues
Categories
Anemia Resources
HOPA Corner
Web Exclusives
All Web Exclusives
Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer
Did You Know? Beyond the Data
Case-Based Exchanges
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ESMO 2025 - Early Breast Cancer
ASCO 2025 - Breast Cancer Faculty Commentary
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Biosimilar Resources
Managing Adverse Events in Patients Utilizing Antibody-Drug Conjugate Therapy
Voices From ASCO 2025
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
Quick Quiz
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor/Perspectives
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
Editorial Board
Editorial Process
Advertising Policy
Advertise
Subscribe
Home
Articles
Latest Issue
Issue Archive
Online First
Special Issues
Categories
Anemia Resources
HOPA Corner
Web Exclusives
All Web Exclusives
Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer
Did You Know? Beyond the Data
Case-Based Exchanges
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ESMO 2025 - Early Breast Cancer
ASCO 2025 - Breast Cancer Faculty Commentary
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Biosimilar Resources
Managing Adverse Events in Patients Utilizing Antibody-Drug Conjugate Therapy
Voices From ASCO 2025
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
Quick Quiz
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor/Perspectives
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
Editorial Board
Editorial Process
Advertising Policy
Advertise
Sintilimab with CapeOx Demonstrates Promising Efficacy and Manageable Safety Profile as Neoadjuvant Therapy in Patients with Locally Advanced, Resectable Gastric/GEJ Cancer
Read More
MAHOGANY: Margetuximab and Retifanlimab Combination Is Well-Tolerated in Patients with HER2-Positive, PD-L1–Positive, Metastatic Gastroesophageal Adenocarcinoma
Read More
CIRCUIT: Nivolumab Combined with Radiotherapy in Patients with Advanced Gastric Cancer Yields Promising Responses
Read More
FIGHT: Significant Improvement in Overall Survival Found in Patients with Advanced Gastric Cancer Treated with Bemarituzumab and Modified FOLFOX6
Read More
ESCORT-1: First-Line Treatment of Camrelizumab with Chemotherapy Improves ESCC Overall Survival
Read More
2021 Gastrointestinal Cancer Year in Review
Joseph Chao, MD
Read More
KEYNOTE-811: Pembrolizumab Added to First-Line Standard of Care Improves Response in HER2-Positive Advanced Gastric or GEJ Cancer
Read More
GAMMA-1 Clinical Trial Results Show Andecaliximab plus mFOLFOX6 Efficacy in Elderly Patients
Read More
Ramucirumab and Irinotecan Combination in Patients with Advanced Gastric Cancer Demonstrates Antitumor Activity
Read More
PRODIGY Clinical Study Meets Primary End Point
Read More
1
2
3
Page 2 of 3
Results 11 - 20 of 30
